CIS Biotech Overview

  • Founded
  • 2000
Founded
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $4M
Latest Deal Amount

CIS Biotech General Information

Description

Provider of research and development services focusing on stroke and brain attack. The company offers research and development services focused on bringing to the marketplace disease-associated biomarkers and in-vitro diagnostic (IVD) tools to provide serological assessment of stroke or brain attack.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 2701 North Decatur Road
  • Main Laboratory
  • Decatur, GA 30033
  • United States
+1 (404) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CIS Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 18-Oct-2013 $4M 00.00 Completed Generating Revenue
2. Angel (individual) 14-Jul-2010 0000 00000 Completed Generating Revenue
1. Angel (individual) 24-Jun-2008 $150K $150K Completed Generating Revenue
To view CIS Biotech’s complete valuation and funding history, request access »

CIS Biotech Patents

CIS Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100210816-A1 Nmdar biomarkers for diagnosing and treating cerebral ischemia Abandoned 12-Dec-2006 0000000000 0
US-20120083586-A1 Nmdar biomarkers for diagnosing and treating cerebral ischemia Abandoned 12-Dec-2006 0000000000
US-7658911-B2 Measuring the level of nr2a and/or nr2b nmda receptor within three hours after stroke onset; for diagnosing stroke in an emergency room setting Expired - Fee Related 27-Jun-2001 00000000000 0
US-7622114-B2 Measuring the level of nr2a and/or nr2b nmda receptor; for diagnosing stroke in an emergency room setting Expired - Fee Related 27-Jun-2001 00000000000 0
US-20060172342-A1 Measuring the level of nr2a and/or nr2b nmda receptor within three hours after stroke onset; for diagnosing stroke in an emergency room setting Granted 27-Jun-2001 G01N33/9406 0

CIS Biotech Executive Team (3)

Name Title Board Seat Contact Info
Robert Rhinehart President
Galina Izykenova Chief Technology Officer & Board Member
You’re viewing 2 of 3 executive team members. Get the full list »

CIS Biotech Board Members (2)

Name Representing Role Since
Galina Izykenova CIS Biotech Chief Technology Officer & Board Member 000 0000
Svetlana Dambinova CIS Biotech Chairman 000 0000
To view CIS Biotech’s complete board members history, request access »